Fulgent Genetics reports a $13.2 million third-quarter loss

Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026.Third Quarter 2026 Results:Non…

Fulgent reported third-quarter 2026 results and updated its full-year outlook, citing improved collection rates and progress addressing a billing system issue. The release text provides no financial figures or revised guidance values.Material DetailsContext by AI AnalystThis is a quarterly results…